Rachna Shroff, MD
Enriched profileChief, Division of Hematology/Oncology, Department of Medicine; John and Valli Duval Endowed Professor in Gastrointestinal Oncology; Professor of Medicine (Tenured), University of Arizona College of Medicine – Tucson · University of Arizona College of Medicine
Rachna Shroff is Chief, Division of Hematology/Oncology, Department of Medicine; John and Valli Duval Endowed Professor in Gastrointestinal Oncology; Professor of Medicine (Tenured), University of Arizona College of Medicine – Tucson at University of Arizona College of Medicine. OpenAlex indexes 395 publications with 17,357 citations (h-index 49); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Rachna Shroff, MD, is Chief, Division of Hematology/Oncology, Department of Medicine at University of Arizona College of Medicine – Tucson / University of Arizona Cancer Center. The public record shows 395 publications with 17,357 citations (h-index 49), centered on Pancreatic and Hepatic Oncology Research, Cholangiocarcinoma and Gallbladder Cancer Studies, Cancer Genomics and Diagnostics. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 33 companies, 4 NIH-funded awards (2019–2026).
- Most recent indexed publication: 2026 · Oncogene
- Top research focus: Pancreatic and Hepatic Oncology Research
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 33 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 21 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 116.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Immune Response to the COVID-19 Vaccine
Sponsor: University of Arizona
Industry payments
Updated 27 Aug 2026
33 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202513 payments$10,932openpaymentsdata.cms.gov ↗
- Ipsen Biopharmaceuticals, IncProgram year20254 payments
- AstraZeneca UK LimitedProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
40%Phenothiazine22.3%Prochlorperazine Maleate100%Part D≥41 patientsOpioid Agonist9%Oxycodone Hcl100%Part D≥16 patientsMetabolism & gastrointestinal
31.7%Serotonin-3 Receptor Antagonist18.3%Ondansetron Odt100%Part D≥42 patientsAntidiarrheal microorganisms9.7%Creon100%Part D≥11 patientsCardiovascular
14.7%Antiarrhythmic14.7%Lidocaine-Prilocaine100%Part D≥34 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
4 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- Establishing the University of Arizona Cancer Center as a Lead Academic Participating Site in the National Clinical Trials Network
University of Arizona
FY2026$310,412UG1CA308474
Congress activity
Updated 27 Aug 2026
133 congress contributions (2008–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract CT164: A phase II trial of cabozantinib with atezolizumab in refractory, metastatic pancreatic adenocarcinoma
AACR Annual Meeting
AACR2026Presenting author - Decoding molecular, clinico-pathological, and outcome differences between early-onset (EO, <50 years) and late-onset (LO, ≥50 years) mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer (CRC): Insights from real-world data.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.
Nature medicine
Clinical Trial2026 - Engineered exosomes with Kras(G12D) specific siRNA in pancreatic cancer: a phase I study with immunological correlates.
Nature communications
Clinical Trial2025 - Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma.
Clinical cancer research
Article2025
Most-cited works
by citation count (OpenAlex)- 01Pancreatic cancerArticle2,545 citations2020
- 02Integrated Genomic Characterization of Pancreatic Ductal AdenocarcinomaArticle2,090 citations2017
- 03
- 04Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced CholangiocarcinomaArticle719 citations2017
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/rachna-shroff-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/rachna-shroff-md-fasco-5bb866115
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - X / Twitter
x.com/rachnatshroff
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/university-of-arizona-cancer-center_great-opportunity-with-rachna-shroff-md-activity-7284712746347085824-vKII
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
connection.asco.org/do/meet-dr-rachna-shroff
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connection.asco.org ↗ - Other
society.asco.org/people/rachna-t-shroff-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →society.asco.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MS
Patient-Based Biological Research, University of Texas Graduate School of Biomedical Sciences, Houston
2012verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.arizona.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.arizona.edu ↗
- Board Certified in Medical Oncology
American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.arizona.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancercenter.arizona.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancercenter.arizona.edu ↗
- Co-Chair
Hepatobiliary Subcommittee, Southwest Oncology Group (SWOG)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancercenter.arizona.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.arizona.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.arizona.edu ↗
Secondary affiliations
appointments beyond the home institution- Medical Director
Oncology Service Line, Banner University Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.arizona.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- Guest
The Medicine Mentors Podcast, "Define Your Legacy with Dr. Rachna Shroff"
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →themedicinementors.libsyn.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.